Chemistry and pharmacology of naproxen.
The need for a nonsteroidal anti-inflammatory agent effective in rheumatoid arthritis, osteoarthritis, gout, ankylosing spondylitis and related diseases with reduced side effects when compared to existing drugs led us to develop naproxen: d-2-(6'-methoxy-2'-naphthyl)-propionic acid. This new agent is a highly effective anti-inflammatory, analgetic, and antipyretic agent in the rodent administered orally. In a rat paw edema test for anti-inflammatory activity naproxen was 55 times more active than aspirin. Analgetic activity was assessed by three different assay procedures. In the mouse phenylquinone writhing test naproxen was 7 times as effective as aspirin. In the rat yeast-induced paw edema and the rat carrageenin paw edema analgetic assays the test compound was 10 and 20 times more effective than aspirin, respectively. A yeast-induced pyresis model in the rat indicated that naproxen was 22 times more potent than the standard aspirin. The relative potency of naproxen to phenylbutazone and indometacin is presented.
D000284:Administration, Oral; D000315:Adrenalectomy; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D002351:Carrageenan; D004353:Drug Evaluation, Preclinical; D004487:Edema / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000188:drug therapy; D006099:Granuloma / Q000188:drug therapy; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009280:Naphthaleneacetic Acids / Q000627:therapeutic use*; D009288:Naproxen / Q000627:therapeutic use*; D010653:Phenylbutazone / Q000627:therapeutic use; D011312:Pressure; D011809:Quinones; D051381:Rats; D015002:Yeast, Dried
D009280:Naphthaleneacetic Acids; D011809:Quinones; D009288:Naproxen; D002351:Carrageenan; D010653:Phenylbutazone; D001241:Aspirin; D007213:Indomethacin